Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML

• ClinicalTrials.gov Identifier: NCT00702403
• Recruitment Status: Completed
• First Posted: June 20, 2008
• Results First Posted: May 15, 2017
• Last Update Posted: August 10, 2017
• Sponsor: Fred Hutchinson Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Information provided by (Responsible Party): Paul Carpenter, Fred Hutchinson Cancer Center

Study Description

Brief Summary:

This phase I/II trial is studying the side effects and best way to give nilotinib when given alone or sequentially after imatinib mesylate after donor stem cell transplant in treating patients with acute lymphoblastic leukemia or chronic myelogenous leukemia. Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Condition or disease	Intervention/treatment	Phase
Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Phase Chronic Myelogenous Leukemia; Philadelphia Positive Adult Acute Lymphoblastic Leukemia; Philadelphia Positive Childhood Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Relapsing Chronic Myelogenous Leukemia; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia	Drug: nilotinib; Drug: imatinib mesylate; Other: pharmacological study	Phase 1; Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To determine the safety of the administration of nilotinib between Day 81 and Day 365 after hematopoietic cell transplantation (HCT) in patients with Philadelphia chromosome positive (Ph+) leukemia.

SECONDARY OBJECTIVES:

I. To quantify the breakpoint cluster region (BCR)/Abelson murine leukemia (ABL) transcript load after HCT during tyrosine kinase inhibitor therapy in patients with Ph+ leukemia treated sequentially with imatinib (imatinib mesylate) and nilotinib from the time of engraftment.

II. To evaluate survival at 1 year in patients with Ph+ leukemia who received sequential imatinib and nilotinib from the time of engraftment.

III. To determine if imatinib can be co-administered with nilotinib for patients with rising levels of BCR/ABL on 2 consecutive occasions after HCT.

IV. To confirm that imatinib can be delivered at an average daily dose of 400 mg at least 85% of the time in the majority of adults during the first 80 days after HCT.

V. To determine whether nilotinib can be administered safely at a daily dose of at least 300 mg (175 mg/m^2 in children < 17 years) at least 70% of the time to patients with imatinib resistant Ph+ leukemia during the first 80 days after HCT.

VI. To determine treatment efficacy success at 1 year post-transplant as demonstrated by complete hematological remission, absence of Philadelphia chromosome, and not satisfying any of the criteria for treatment failure.

OUTLINE:

Beginning after engraftment and blood count recovery (21-28 days after allogeneic stem cell transplant), patients with imatinib-sensitive leukemia receive imatinib mesylate orally (PO) once daily (QD) until day 80 and then nilotinib PO twice daily (BID) on days 81-445. Patients with imatinib-resistant leukemia receive nilotinib PO BID beginning after engraftment and blood count recovery until day 445.

Treatment continues in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 40 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Multicenter Phase I/II Study of the Prophylactic Inhibition of BCR-ABL Tyrosine Kinase by Tasigna ® (Nilotinib) After Hematopoietic Cell Transplantation for Philadelphia Chromosome-Positive Leukemias.
• Actual Study Start Date: August 14, 2008
• Actual Primary Completion Date: December 2013
• Actual Study Completion Date: December 1, 2013

Arms and Interventions

Arm

Intervention/treatment

Experimental: Treatment (prophylactic inhibition of BCR-ABL tyrosine kinase); Beginning after engraftment and blood count recovery (21 to 28 days after allogeneic stem cell transplant), patients with imatinib-sensitive leukemia receive imatinib mesylate PO QD until day 80 and then nilotinib PO BID on days 81-445. Patients with imatinib-resistant leukemia receive nilotinib PO BID beginning after engraftment and blood count recovery until day 445. Treatment continues in the absence of disease progression or unacceptable toxicity.

Drug: nilotinib; Given PO; Other Names: AMN 107; Tasigna; Drug: imatinib mesylate; Given PO; Other Names: CGP 57148; Gleevec; Glivec; Other: pharmacological study; Correlative studies; Other Name: pharmacological studies

Outcome Measures

Primary Outcome Measures :

1. Number of Participants With Treatment Safety Failure [ Time Frame: Up to 365 days post-transplant ]
   Safety and tolerability of nilotinib therapy in patients with imatinib-sensitive leukemia graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.0. Treatment safety failure is defined for a patient with imatinib sensitive Ph+ leukemia as the inability to be able to deliver at least 400 milligrams per day of nilotinib in adults, and 230 milligrams/m2 per day in children, for at least 85% of the time interval between 81 and 365 days after transplant. The overall study will be considered successful if nilotinib is deliverable to more than 75% of the study participants at this minimum specified dose intensity.

Secondary Outcome Measures :

1. The Proportion of Patients at 1 Year With Treatment Efficacy Success [ Time Frame: Up to 1 year ]
   To be considered a treatment efficacy success at 1 year posttransplant, the patient's bone marrow must demonstrate complete hematological remission, absence of Philadelphia chromosomes, and not satisfy any of the criteria for treatment failure (>/= 1% aberrantly expressing marrow blasts by multiparameter flow cytometry, >5% BCR/ABL in marrow by fluorescent in situ hybridization, or >1 log rise in peripheral blood BCR/ABL by quantitative polymerase chain reaction (PCR) since day 80).
2. Survival [ Time Frame: Up to 3 years ]
   The proportion of study participants alive at 1, 2 and 3 years
3. Patients Alive With Out Relapse [ Time Frame: Up to 1 year ]
   The proportion of study participants alive and without hematologic, cytogenetic or molecular evidence of BCR/ABL-positive leukemia at 1 year
4. Relapse [ Time Frame: 1 and 3 years ]
   The proportion of patients with hematologic, cytogenetic or molecular relapse of BCR/ABL-positive leukemia

Eligibility Criteria

• Ages Eligible for Study: Child, Adult, Older Adult
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Body surface area >= 1 m^2
• Allogeneic HCT
• Acute lymphocytic leukemia (ALL) or chronic myelogenous leukemia (CML) characterized by the p190 and/or p210 BCR/ABL gene rearrangement
• CML in accelerated phase, blast crisis, or blast crisis remission as defined by World Health Organization (WHO) criteria
• CML in chronic phase if patient age =< 17 years or a patient of any age with CML in second chronic phase or beyond
• Patients with minimal residual disease (MRD) that is not declining in response to tyrosine kinase inhibitor therapy must be screened for the T315I and other mutations
• An appropriately matched related or unrelated donor
• Signed informed consent
• Patient must have a life expectancy of at least 2 months
• Stated willingness of the patient to comply with study procedures and reporting requirements
• Creatinine =< 2.0 x upper limit normal (ULN)
• Platelets > 20 x 10^9 /L
• Serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN, conjugated bilirubin < 3 x ULN
• Serum potassium phosphorus, magnesium, and calcium >= lower limit normal (LLN) or correctable with supplements prior to first dose of study drug; calcium levels may be corrected for hypoalbuminemia
• Serum amylase and lipase < 1.5 x ULN
• Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing; postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential; male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug
• Careful rationalization with a view to discontinuing or considering alternatives to any concomitant medications that have potential to prolong the QT interval

Exclusion Criteria:

• Autologous transplant
• Non-myeloablative transplant
• Patient age > 17 years with CML in first chronic phase
• Aberrant antigen expression on marrow leukemic blasts >= 5% by multidimensional flow cytometric assay immediately before conditioning (CML patients in chronic phase exempt from flow cytometry screening)
• Ph+ ALL without complete cytogenetic remission immediately before conditioning
• Known T315I mutation
• Hypersensitivity to Gleevec or Tasigna
• Patients who are Tasigna-resistant or intolerant
• Central nervous system (CNS) involvement with leukemia at baseline (pre-imatinib therapy); CML chronic phase (CP), accelerated phase (AP) patients exempt from CNS involvement screening
• Female patients who are pregnant, breast-feeding, or of childbearing potential without a negative serum pregnancy test at screening; male or female patients of childbearing potential unwilling to use effective contraceptive precautions throughout the trial; post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential
• Life expectancy severely limited by diseases other than leukemia
• Myocardial infarction within one year prior to starting nilotinib
• Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, unstable angina)
• Absolute neutrophil count (ANC) less than 1500 per microliter at study entry despite the use of filgrastim (G-CSF)

• Impaired cardiac function, including any one of the following:

  • Complete left bundle branch block or bifascicular block (right bundle branch block plus left anterior hemiblock) or use of ventricular-paced pacemaker
  • Congenital long QT syndrome or a family history of long QT syndrome
  • History of or presence of significant ventricular or atrial tachyarrhythmias
  • Clinically significant resting bradycardia (< 50 beats per minute)
• Corrected QT interval (QTc) > 450 milliseconds on screening electrocardiogram (ECG); if QTc > 450 and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient rescreened for QTc

Contacts and Locations

Locations

United States, California

Stanford University Hospitals and Clinics

Stanford, California, United States, 94305

United States, Florida

H Lee Moffitt Cancer Center and Research Institute Phase 2 Consortium

Tampa, Florida, United States, 33612

H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, United States, 33612

United States, Oregon

Oregon Health and Science University

Portland, Oregon, United States, 97239

United States, Washington

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Seattle, Washington, United States, 98109

Sponsors and Collaborators

Fred Hutchinson Cancer Center

National Cancer Institute (NCI)

Investigators

• Principal Investigator: Paul Carpenter; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

More Information

• Responsible Party: Paul Carpenter, Principal Investigator, Fred Hutchinson Cancer Center
• ClinicalTrials.gov Identifier: NCT00702403
• Other Study ID Numbers: 2223.00; NCI-2010-00402 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ); P30CA015704 ( U.S. NIH Grant/Contract ); P01CA018029 ( U.S. NIH Grant/Contract )
• First Posted: June 20, 2008
• Results First Posted: May 15, 2017
• Last Update Posted: August 10, 2017
• Last Verified: July 2017

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Additional relevant MeSH terms:

Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Blast Crisis; Leukemia, Myeloid, Accelerated Phase; Recurrence; Neoplasms by Histologic Type; Neoplasms; Disease Attributes; Pathologic Processes; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Myeloproliferative Disorders; Bone Marrow Diseases; Hematologic Diseases; Cell Transformation, Neoplastic; Carcinogenesis; Neoplastic Processes; Imatinib Mesylate; Antineoplastic Agents; Protein Kinase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action